Denali Therapeutics Inc.
DNL628
Alzheimer's disease
Countdown
358days
Phase 1 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 1 trial results for DNL628 in Alzheimer's disease are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Denali expects data from this study in 1H 2027.”